AGY

The allergy epidemic: is a cure on the way?

A spiralling health crisis threatens countless children and makes parents’ lives intolerable—and nobody understands what’s causing it. But hope could be round the corner A Worthing-based biotech company, Allergy Therapeutics,

Allergy Therapeutics to host KOL webinar on VLP Peanut

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced that it will host a webinar entitled ‘VLP Peanut; a next generation peanut

Peanut allergy: What you should know

Peanuts were once a snack-time staple, but these days, they are largely off-limits for a growing number of kids and adults. It’s common now not to serve certain foods at

How to dine out safely with food allergies

The first time I piped up about my food intolerances, my voice shook. I’d been diagnosed with a gut condition I won’t bore you with (thus explaining the gnarly way

Food allergies are on the rise

According to The New York Times, food allergies are far more complicated than we once thought. Jane E. Brody’s grandson, Tomas, is allergic to hazelnuts and raw carrots. Not because

STRIX GROUP PLC ORD 1P
Strix Group plc CEO Mark Bartlett discusses the company's focus on safety controls, global reach, innovation, and growth opportunities for investors.
Firering Strategic MineralS PLC
Learn about Firering Strategic Minerals plc's operations and future plans from an exclusive interview with their Independent Non-Executive Director, Vassilios Carellas.
Pulsar Helium Inc
Discover insights into the helium sector as Stephane Foucard delves into the projects of junior companies, assessing key criteria for commercial viability.
Golden Matrix Group Inc
Golden Matrix Group Inc. CEO Brian Goodman discusses revenue growth, acquisitions, and global markets in an exclusive interview with DirectorsTalk.
XP Factory plc
XP Factory plc's CEO discusses financial highlights, growth targets, and a £10 million credit facility with Barclays in an exclusive interview with DirectorsTalk.